Type 2 Diabetes Program

About Clinical Research of Philadelphia

Clinical Research of Philadelphia (CRP) is a well-established, privately-held clinical research site that has been serving the Philadelphia community for nearly three decades. The company's mission is to advance medical research by connecting diverse patient populations with clinical trials, leveraging partnerships with over 50 community-based providers to access a potential patient pool of over 600,000. CRP has built a strong reputation for operational excellence, having enrolled over 10,000 participants since its founding, and focuses on therapeutic areas with high unmet need, including metabolic dysfunction-associated steatotic liver disease (MASLD), cardiovascular risk, type 2 diabetes, and women's health conditions. Their patient-centric approach, technological infrastructure, and experienced team position them as a preferred site for pharmaceutical sponsors.

About SeNostic

SeNostic is a private, pre-revenue diagnostics and drug discovery platform company targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, as well as Type 2 Diabetes. Its proprietary SeedCycler® technology utilizes a protein amplification method, similar to PCR, to detect and analyze disease-specific misfolded protein aggregates (e.g., α-synuclein, amyloid-β) from biofluids. The company aims to serve the high-unmet-need markets of early disease diagnostics, patient stratification for clinical trials, and pre-clinical drug screening, with a business model encompassing device sales, consumables, assays, and recombinant protein reagents.

Therapeutic Areas

Other Type 2 Diabetes Mellitus Drugs